Dr Reddy's Laboratories has received tentative approval from the US Food and Drug Administration (FDA) for a generic version of lenacapavir, a long-acting HIV prevention drug administered twice a year. The development could improve access to HIV prevention treatment across several developing countries.

AdvertisementThe Puranic

The Indian pharmaceutical company is planning to introduce the generic version in 120 developing countries later this year, according to the supplied announcement. The move is expected to strengthen the availability of affordable HIV prevention options, particularly in regions where access to advanced preventive medicines remains limited.

Lenacapavir is a long-acting injectable medicine designed to reduce the risk of acquiring HIV. Unlike conventional prevention medicines that require frequent dosing, the twice-yearly injection offers a less frequent treatment schedule, potentially making preventive care more convenient for eligible individuals.

The development also highlights the growing role of Indian pharmaceutical manufacturers in expanding access to important medicines across international markets.

Tentative FDA approval is an important regulatory milestone, although it should not be confused with final approval or unrestricted commercial marketing authorisation in every country. The planned rollout will also depend on applicable regulatory requirements and supply arrangements in individual markets.

For Dr Reddy's, the development represents an opportunity to expand its global presence in the HIV treatment and prevention segment while contributing to wider access to long-acting preventive medicines.